While NOX4 inhibitors have not yet been tested in clinical trials specifically for cardiac diseases, preclinical data support their potential therapeutic benefits in conditions such as myocardial infarction, heart failure, and ischemia–reperfusion injury. This evidence concerns the gene NOX4 and myocardial infarction.